Latest AviadoBio News & Updates

See the latest news and media coverage for AviadoBio. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
AviadoBio

Gene therapy biotechnology company focused on neurodegenerative diseases

aviadobio.com
Headquarters
London, United Kingdom
Founded year
2019
Company type
Private company
Number of employees
50–71

Last updated

Latest news about AviadoBio

In short: AviadoBio reported new vMiX preclinical results and planned AVB-406’s first-in-human study for 2027.

Company announcements

AviadoBio

AviadoBio grants Astellas option to license AVB-101

Astellas makes a $20 million equity investment and up to $30 million in upfront payments, with up to $2.18 billion in milestone payments plus royalties.

Unlock all announcements with a

Media coverage

MedCity News

Biotech startup AviadoBio emerges with $80M for neuro disorder gene therapies

The lead program of AviadoBio is a gene therapy for frontotemporal dementia. The London-based startup plans to use the Series A round of funding to...

Unlock all articles with a

Never miss news about AviadoBio

Track AviadoBio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.